nodes	percent_of_prediction	percent_of_DWPC	metapath
Vemurafenib—melanoma—skin cancer	0.279	1	CtDrD
Vemurafenib—Etoricoxib—Vismodegib—skin cancer	0.275	1	CrCrCtD
Vemurafenib—BRAF—skin cancer	0.199	1	CbGaD
Vemurafenib—ORM1—Vismodegib—skin cancer	0.0376	0.21	CbGbCtD
Vemurafenib—ABCG2—Vismodegib—skin cancer	0.023	0.128	CbGbCtD
Vemurafenib—ABCC1—Dactinomycin—skin cancer	0.018	0.101	CbGbCtD
Vemurafenib—ALB—Vismodegib—skin cancer	0.0158	0.0883	CbGbCtD
Vemurafenib—CYP1A2—Imiquimod—skin cancer	0.0137	0.0762	CbGbCtD
Vemurafenib—ABCG2—Dactinomycin—skin cancer	0.0121	0.0673	CbGbCtD
Vemurafenib—ABCC1—Docetaxel—skin cancer	0.0093	0.0519	CbGbCtD
Vemurafenib—ABCG2—Fluorouracil—skin cancer	0.00815	0.0455	CbGbCtD
Vemurafenib—CYP3A4—Temozolomide—skin cancer	0.00715	0.0399	CbGbCtD
Vemurafenib—CYP3A4—Imiquimod—skin cancer	0.00715	0.0399	CbGbCtD
Vemurafenib—ABCG2—Docetaxel—skin cancer	0.00623	0.0348	CbGbCtD
Vemurafenib—CYP1A2—Dacarbazine—skin cancer	0.00573	0.032	CbGbCtD
Vemurafenib—ALB—Fluorouracil—skin cancer	0.00562	0.0314	CbGbCtD
Vemurafenib—CYP3A4—Vismodegib—skin cancer	0.00496	0.0277	CbGbCtD
Vemurafenib—Actinic keratosis—Imiquimod—skin cancer	0.0037	0.0928	CcSEcCtD
Vemurafenib—CYP1A2—Fluorouracil—skin cancer	0.00336	0.0188	CbGbCtD
Vemurafenib—Seborrhoeic keratosis—Imiquimod—skin cancer	0.00294	0.0738	CcSEcCtD
Vemurafenib—Common wart—Imiquimod—skin cancer	0.00212	0.0533	CcSEcCtD
Vemurafenib—Squamous cell carcinoma—Imiquimod—skin cancer	0.00136	0.0341	CcSEcCtD
Vemurafenib—CYP3A4—Docetaxel—skin cancer	0.00134	0.00751	CbGbCtD
Vemurafenib—Basal cell carcinoma—Imiquimod—skin cancer	0.00131	0.0328	CcSEcCtD
Vemurafenib—Hyperkeratosis—Imiquimod—skin cancer	0.00108	0.0271	CcSEcCtD
Vemurafenib—Skin papilloma—Imiquimod—skin cancer	0.000946	0.0237	CcSEcCtD
Vemurafenib—Hyperkeratosis—Bleomycin—skin cancer	0.000766	0.0192	CcSEcCtD
Vemurafenib—Neoplasm malignant—Vismodegib—skin cancer	0.000685	0.0172	CcSEcCtD
Vemurafenib—Musculoskeletal pain—Vismodegib—skin cancer	0.000592	0.0149	CcSEcCtD
Vemurafenib—Folliculitis—Imiquimod—skin cancer	0.000491	0.0123	CcSEcCtD
Vemurafenib—Cyst—Imiquimod—skin cancer	0.000461	0.0116	CcSEcCtD
Vemurafenib—Etoricoxib—PTGS2—skin cancer	0.000459	1	CrCbGaD
Vemurafenib—Pain in extremity—Vismodegib—skin cancer	0.000425	0.0107	CcSEcCtD
Vemurafenib—RAF1—hair follicle—skin cancer	0.000391	0.125	CbGeAlD
Vemurafenib—Rigors—Imiquimod—skin cancer	0.000378	0.00948	CcSEcCtD
Vemurafenib—Weight decreased—Vismodegib—skin cancer	0.000332	0.00834	CcSEcCtD
Vemurafenib—Folliculitis—Dactinomycin—skin cancer	0.000325	0.00816	CcSEcCtD
Vemurafenib—Rash generalised—Docetaxel—skin cancer	0.000289	0.00725	CcSEcCtD
Vemurafenib—Connective tissue disorder—Vismodegib—skin cancer	0.000289	0.00725	CcSEcCtD
Vemurafenib—RAF1—nipple—skin cancer	0.000265	0.0847	CbGeAlD
Vemurafenib—Hepatotoxicity—Dactinomycin—skin cancer	0.000265	0.00664	CcSEcCtD
Vemurafenib—RAF1—neck—skin cancer	0.000262	0.0838	CbGeAlD
Vemurafenib—Alopecia—Vismodegib—skin cancer	0.00026	0.00652	CcSEcCtD
Vemurafenib—Malnutrition—Vismodegib—skin cancer	0.000256	0.00642	CcSEcCtD
Vemurafenib—Dysgeusia—Vismodegib—skin cancer	0.000251	0.00629	CcSEcCtD
Vemurafenib—Back pain—Vismodegib—skin cancer	0.000247	0.00621	CcSEcCtD
Vemurafenib—Hepatotoxicity—Temozolomide—skin cancer	0.000239	0.006	CcSEcCtD
Vemurafenib—Atrial fibrillation—Imiquimod—skin cancer	0.000236	0.00593	CcSEcCtD
Vemurafenib—Arthritis—Imiquimod—skin cancer	0.00023	0.00578	CcSEcCtD
Vemurafenib—Rigors—Temozolomide—skin cancer	0.000226	0.00568	CcSEcCtD
Vemurafenib—Gamma-glutamyltransferase increased—Temozolomide—skin cancer	0.000225	0.00564	CcSEcCtD
Vemurafenib—Pain in extremity—Imiquimod—skin cancer	0.000224	0.00562	CcSEcCtD
Vemurafenib—Arthralgia—Vismodegib—skin cancer	0.000218	0.00547	CcSEcCtD
Vemurafenib—Myalgia—Vismodegib—skin cancer	0.000218	0.00547	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Vismodegib—skin cancer	0.000216	0.00543	CcSEcCtD
Vemurafenib—Nervous system disorder—Vismodegib—skin cancer	0.000205	0.00514	CcSEcCtD
Vemurafenib—Skin disorder—Vismodegib—skin cancer	0.000203	0.00509	CcSEcCtD
Vemurafenib—Polyp—Docetaxel—skin cancer	0.000202	0.00507	CcSEcCtD
Vemurafenib—ABCC1—hair follicle—skin cancer	0.000195	0.0624	CbGeAlD
Vemurafenib—Musculoskeletal discomfort—Vismodegib—skin cancer	0.00019	0.00477	CcSEcCtD
Vemurafenib—RAF1—connective tissue—skin cancer	0.000188	0.0601	CbGeAlD
Vemurafenib—Musculoskeletal pain—Temozolomide—skin cancer	0.000187	0.00469	CcSEcCtD
Vemurafenib—Cyst—Docetaxel—skin cancer	0.000184	0.00461	CcSEcCtD
Vemurafenib—Decreased appetite—Vismodegib—skin cancer	0.000181	0.00455	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Vismodegib—skin cancer	0.00018	0.00452	CcSEcCtD
Vemurafenib—Fatigue—Vismodegib—skin cancer	0.00018	0.00452	CcSEcCtD
Vemurafenib—Constipation—Vismodegib—skin cancer	0.000179	0.00448	CcSEcCtD
Vemurafenib—RAF1—epithelium—skin cancer	0.000178	0.057	CbGeAlD
Vemurafenib—Photosensitivity reaction—Imiquimod—skin cancer	0.000177	0.00443	CcSEcCtD
Vemurafenib—Infestation NOS—Imiquimod—skin cancer	0.000172	0.00433	CcSEcCtD
Vemurafenib—Infestation—Imiquimod—skin cancer	0.000172	0.00433	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Imiquimod—skin cancer	0.000171	0.00429	CcSEcCtD
Vemurafenib—RAF1—skin of body—skin cancer	0.00017	0.0543	CbGeAlD
Vemurafenib—Neuropathy peripheral—Imiquimod—skin cancer	0.000169	0.00424	CcSEcCtD
Vemurafenib—Neoplasm—Temozolomide—skin cancer	0.000167	0.00419	CcSEcCtD
Vemurafenib—Arthritis—Bleomycin—skin cancer	0.000164	0.00411	CcSEcCtD
Vemurafenib—Hepatotoxicity—Docetaxel—skin cancer	0.000159	0.00399	CcSEcCtD
Vemurafenib—RAF1—mammalian vulva—skin cancer	0.000155	0.0495	CbGeAlD
Vemurafenib—Rash maculo-papular—Fluorouracil—skin cancer	0.000155	0.00388	CcSEcCtD
Vemurafenib—Connective tissue disorder—Imiquimod—skin cancer	0.000152	0.00382	CcSEcCtD
Vemurafenib—Rigors—Docetaxel—skin cancer	0.00015	0.00378	CcSEcCtD
Vemurafenib—Asthenia—Vismodegib—skin cancer	0.00015	0.00376	CcSEcCtD
Vemurafenib—Pruritus—Vismodegib—skin cancer	0.000148	0.00371	CcSEcCtD
Vemurafenib—Erythema multiforme—Imiquimod—skin cancer	0.000146	0.00367	CcSEcCtD
Vemurafenib—Eye disorder—Imiquimod—skin cancer	0.000145	0.00363	CcSEcCtD
Vemurafenib—Diarrhoea—Vismodegib—skin cancer	0.000143	0.00358	CcSEcCtD
Vemurafenib—Photosensitivity—Fluorouracil—skin cancer	0.000141	0.00353	CcSEcCtD
Vemurafenib—Angiopathy—Imiquimod—skin cancer	0.00014	0.00353	CcSEcCtD
Vemurafenib—Mediastinal disorder—Imiquimod—skin cancer	0.00014	0.0035	CcSEcCtD
Vemurafenib—Chills—Imiquimod—skin cancer	0.000139	0.00349	CcSEcCtD
Vemurafenib—RAF1—lymphoid tissue—skin cancer	0.000137	0.0439	CbGeAlD
Vemurafenib—Alopecia—Imiquimod—skin cancer	0.000137	0.00343	CcSEcCtD
Vemurafenib—Malnutrition—Imiquimod—skin cancer	0.000135	0.00338	CcSEcCtD
Vemurafenib—Erythema—Imiquimod—skin cancer	0.000135	0.00338	CcSEcCtD
Vemurafenib—Toxic epidermal necrolysis—Dactinomycin—skin cancer	0.000134	0.00335	CcSEcCtD
Vemurafenib—Vomiting—Vismodegib—skin cancer	0.000133	0.00333	CcSEcCtD
Vemurafenib—RAF1—female reproductive system—skin cancer	0.000133	0.0424	CbGeAlD
Vemurafenib—ABCC1—nipple—skin cancer	0.000132	0.0423	CbGeAlD
Vemurafenib—Rash—Vismodegib—skin cancer	0.000132	0.0033	CcSEcCtD
Vemurafenib—Dermatitis—Vismodegib—skin cancer	0.000132	0.0033	CcSEcCtD
Vemurafenib—Back pain—Imiquimod—skin cancer	0.00013	0.00327	CcSEcCtD
Vemurafenib—Weight decreased—Bleomycin—skin cancer	0.000124	0.00312	CcSEcCtD
Vemurafenib—Nausea—Vismodegib—skin cancer	0.000124	0.00311	CcSEcCtD
Vemurafenib—Dry skin—Temozolomide—skin cancer	0.000123	0.00308	CcSEcCtD
Vemurafenib—Toxic epidermal necrolysis—Temozolomide—skin cancer	0.000121	0.00303	CcSEcCtD
Vemurafenib—Cough—Imiquimod—skin cancer	0.000118	0.00295	CcSEcCtD
Vemurafenib—BRAF—lymph node—skin cancer	0.000116	0.0372	CbGeAlD
Vemurafenib—Arthralgia—Imiquimod—skin cancer	0.000115	0.00288	CcSEcCtD
Vemurafenib—Myalgia—Imiquimod—skin cancer	0.000115	0.00288	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Imiquimod—skin cancer	0.000114	0.00286	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Dactinomycin—skin cancer	0.000113	0.00284	CcSEcCtD
Vemurafenib—Dry skin—Fluorouracil—skin cancer	0.000113	0.00284	CcSEcCtD
Vemurafenib—Neoplasm—Docetaxel—skin cancer	0.000111	0.00279	CcSEcCtD
Vemurafenib—RAF1—head—skin cancer	0.000111	0.0354	CbGeAlD
Vemurafenib—Infection—Imiquimod—skin cancer	0.000109	0.00274	CcSEcCtD
Vemurafenib—Nervous system disorder—Imiquimod—skin cancer	0.000108	0.00271	CcSEcCtD
Vemurafenib—Skin disorder—Imiquimod—skin cancer	0.000107	0.00268	CcSEcCtD
Vemurafenib—Photosensitivity reaction—Temozolomide—skin cancer	0.000106	0.00266	CcSEcCtD
Vemurafenib—Eosinophilia—Fluorouracil—skin cancer	0.000106	0.00265	CcSEcCtD
Vemurafenib—CYP1A2—nipple—skin cancer	0.000106	0.0337	CbGeAlD
Vemurafenib—Weight decreased—Temozolomide—skin cancer	0.000105	0.00263	CcSEcCtD
Vemurafenib—Infestation—Temozolomide—skin cancer	0.000103	0.00259	CcSEcCtD
Vemurafenib—Infestation NOS—Temozolomide—skin cancer	0.000103	0.00259	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Temozolomide—skin cancer	0.000102	0.00257	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Temozolomide—skin cancer	0.000101	0.00254	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Imiquimod—skin cancer	0.0001	0.00251	CcSEcCtD
Vemurafenib—Chills—Bleomycin—skin cancer	9.87e-05	0.00248	CcSEcCtD
Vemurafenib—Photosensitivity reaction—Fluorouracil—skin cancer	9.75e-05	0.00245	CcSEcCtD
Vemurafenib—Alopecia—Bleomycin—skin cancer	9.72e-05	0.00244	CcSEcCtD
Vemurafenib—Erythema multiforme—Dactinomycin—skin cancer	9.7e-05	0.00243	CcSEcCtD
Vemurafenib—Erythema—Bleomycin—skin cancer	9.57e-05	0.0024	CcSEcCtD
Vemurafenib—Decreased appetite—Imiquimod—skin cancer	9.56e-05	0.0024	CcSEcCtD
Vemurafenib—Infestation NOS—Fluorouracil—skin cancer	9.52e-05	0.00239	CcSEcCtD
Vemurafenib—Infestation—Fluorouracil—skin cancer	9.52e-05	0.00239	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Imiquimod—skin cancer	9.5e-05	0.00238	CcSEcCtD
Vemurafenib—Fatigue—Imiquimod—skin cancer	9.48e-05	0.00238	CcSEcCtD
Vemurafenib—Atrial fibrillation—Docetaxel—skin cancer	9.41e-05	0.00236	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Fluorouracil—skin cancer	9.33e-05	0.00234	CcSEcCtD
Vemurafenib—Chills—Dactinomycin—skin cancer	9.2e-05	0.00231	CcSEcCtD
Vemurafenib—ORM1—female reproductive system—skin cancer	9.15e-05	0.0293	CbGeAlD
Vemurafenib—Oedema peripheral—Temozolomide—skin cancer	9.14e-05	0.00229	CcSEcCtD
Vemurafenib—Connective tissue disorder—Temozolomide—skin cancer	9.12e-05	0.00229	CcSEcCtD
Vemurafenib—Alopecia—Dactinomycin—skin cancer	9.06e-05	0.00227	CcSEcCtD
Vemurafenib—Erythema—Dactinomycin—skin cancer	8.93e-05	0.00224	CcSEcCtD
Vemurafenib—Pain in extremity—Docetaxel—skin cancer	8.92e-05	0.00224	CcSEcCtD
Vemurafenib—Erythema multiforme—Temozolomide—skin cancer	8.77e-05	0.0022	CcSEcCtD
Vemurafenib—Body temperature increased—Imiquimod—skin cancer	8.7e-05	0.00218	CcSEcCtD
Vemurafenib—Eye disorder—Temozolomide—skin cancer	8.67e-05	0.00218	CcSEcCtD
Vemurafenib—Cardiac disorder—Temozolomide—skin cancer	8.61e-05	0.00216	CcSEcCtD
Vemurafenib—Angiopathy—Temozolomide—skin cancer	8.42e-05	0.00211	CcSEcCtD
Vemurafenib—Mediastinal disorder—Temozolomide—skin cancer	8.36e-05	0.0021	CcSEcCtD
Vemurafenib—Cough—Bleomycin—skin cancer	8.36e-05	0.0021	CcSEcCtD
Vemurafenib—Chills—Temozolomide—skin cancer	8.33e-05	0.00209	CcSEcCtD
Vemurafenib—Alopecia—Temozolomide—skin cancer	8.2e-05	0.00206	CcSEcCtD
Vemurafenib—Dry skin—Docetaxel—skin cancer	8.18e-05	0.00205	CcSEcCtD
Vemurafenib—Myalgia—Bleomycin—skin cancer	8.15e-05	0.00205	CcSEcCtD
Vemurafenib—Hypersensitivity—Imiquimod—skin cancer	8.1e-05	0.00203	CcSEcCtD
Vemurafenib—Malnutrition—Temozolomide—skin cancer	8.08e-05	0.00203	CcSEcCtD
Vemurafenib—Erythema—Temozolomide—skin cancer	8.08e-05	0.00203	CcSEcCtD
Vemurafenib—Toxic epidermal necrolysis—Docetaxel—skin cancer	8.03e-05	0.00202	CcSEcCtD
Vemurafenib—Dysgeusia—Temozolomide—skin cancer	7.91e-05	0.00198	CcSEcCtD
Vemurafenib—Asthenia—Imiquimod—skin cancer	7.89e-05	0.00198	CcSEcCtD
Vemurafenib—Anaphylactic shock—Bleomycin—skin cancer	7.81e-05	0.00196	CcSEcCtD
Vemurafenib—Back pain—Temozolomide—skin cancer	7.81e-05	0.00196	CcSEcCtD
Vemurafenib—Pruritus—Imiquimod—skin cancer	7.78e-05	0.00195	CcSEcCtD
Vemurafenib—Infection—Bleomycin—skin cancer	7.76e-05	0.00195	CcSEcCtD
Vemurafenib—RAF1—lymph node—skin cancer	7.76e-05	0.0248	CbGeAlD
Vemurafenib—ABCC1—mammalian vulva—skin cancer	7.74e-05	0.0247	CbGeAlD
Vemurafenib—Myalgia—Dactinomycin—skin cancer	7.6e-05	0.00191	CcSEcCtD
Vemurafenib—Alopecia—Fluorouracil—skin cancer	7.55e-05	0.0019	CcSEcCtD
Vemurafenib—Diarrhoea—Imiquimod—skin cancer	7.53e-05	0.00189	CcSEcCtD
Vemurafenib—Erythema—Fluorouracil—skin cancer	7.44e-05	0.00187	CcSEcCtD
Vemurafenib—Hypotension—Bleomycin—skin cancer	7.3e-05	0.00183	CcSEcCtD
Vemurafenib—Dizziness—Imiquimod—skin cancer	7.27e-05	0.00183	CcSEcCtD
Vemurafenib—Infection—Dactinomycin—skin cancer	7.24e-05	0.00182	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Bleomycin—skin cancer	7.12e-05	0.00179	CcSEcCtD
Vemurafenib—Cough—Temozolomide—skin cancer	7.05e-05	0.00177	CcSEcCtD
Vemurafenib—Vomiting—Imiquimod—skin cancer	6.99e-05	0.00176	CcSEcCtD
Vemurafenib—Weight decreased—Docetaxel—skin cancer	6.97e-05	0.00175	CcSEcCtD
Vemurafenib—Rash—Imiquimod—skin cancer	6.94e-05	0.00174	CcSEcCtD
Vemurafenib—Dermatitis—Imiquimod—skin cancer	6.93e-05	0.00174	CcSEcCtD
Vemurafenib—Headache—Imiquimod—skin cancer	6.89e-05	0.00173	CcSEcCtD
Vemurafenib—Arthralgia—Temozolomide—skin cancer	6.88e-05	0.00173	CcSEcCtD
Vemurafenib—Myalgia—Temozolomide—skin cancer	6.88e-05	0.00173	CcSEcCtD
Vemurafenib—Infestation—Docetaxel—skin cancer	6.87e-05	0.00172	CcSEcCtD
Vemurafenib—Infestation NOS—Docetaxel—skin cancer	6.87e-05	0.00172	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	6.83e-05	0.00171	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Docetaxel—skin cancer	6.81e-05	0.00171	CcSEcCtD
Vemurafenib—Decreased appetite—Bleomycin—skin cancer	6.79e-05	0.0017	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Docetaxel—skin cancer	6.74e-05	0.00169	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Dactinomycin—skin cancer	6.64e-05	0.00167	CcSEcCtD
Vemurafenib—Anaphylactic shock—Temozolomide—skin cancer	6.59e-05	0.00165	CcSEcCtD
Vemurafenib—Infection—Temozolomide—skin cancer	6.55e-05	0.00164	CcSEcCtD
Vemurafenib—Nausea—Imiquimod—skin cancer	6.53e-05	0.00164	CcSEcCtD
Vemurafenib—Nervous system disorder—Temozolomide—skin cancer	6.46e-05	0.00162	CcSEcCtD
Vemurafenib—ABCG2—mammalian vulva—skin cancer	6.4e-05	0.0205	CbGeAlD
Vemurafenib—Skin disorder—Temozolomide—skin cancer	6.4e-05	0.00161	CcSEcCtD
Vemurafenib—Myalgia—Fluorouracil—skin cancer	6.34e-05	0.00159	CcSEcCtD
Vemurafenib—Decreased appetite—Dactinomycin—skin cancer	6.34e-05	0.00159	CcSEcCtD
Vemurafenib—Fatigue—Dactinomycin—skin cancer	6.28e-05	0.00158	CcSEcCtD
Vemurafenib—Body temperature increased—Bleomycin—skin cancer	6.18e-05	0.00155	CcSEcCtD
Vemurafenib—Oedema peripheral—Docetaxel—skin cancer	6.08e-05	0.00153	CcSEcCtD
Vemurafenib—Anaphylactic shock—Fluorouracil—skin cancer	6.07e-05	0.00152	CcSEcCtD
Vemurafenib—Connective tissue disorder—Docetaxel—skin cancer	6.06e-05	0.00152	CcSEcCtD
Vemurafenib—Infection—Fluorouracil—skin cancer	6.03e-05	0.00151	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Temozolomide—skin cancer	6.01e-05	0.00151	CcSEcCtD
Vemurafenib—Nervous system disorder—Fluorouracil—skin cancer	5.96e-05	0.00149	CcSEcCtD
Vemurafenib—Erythema multiforme—Docetaxel—skin cancer	5.83e-05	0.00146	CcSEcCtD
Vemurafenib—Eye disorder—Docetaxel—skin cancer	5.77e-05	0.00145	CcSEcCtD
Vemurafenib—Body temperature increased—Dactinomycin—skin cancer	5.76e-05	0.00145	CcSEcCtD
Vemurafenib—Hypersensitivity—Bleomycin—skin cancer	5.76e-05	0.00144	CcSEcCtD
Vemurafenib—Decreased appetite—Temozolomide—skin cancer	5.73e-05	0.00144	CcSEcCtD
Vemurafenib—Cardiac disorder—Docetaxel—skin cancer	5.73e-05	0.00144	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Temozolomide—skin cancer	5.69e-05	0.00143	CcSEcCtD
Vemurafenib—Fatigue—Temozolomide—skin cancer	5.68e-05	0.00143	CcSEcCtD
Vemurafenib—Hypotension—Fluorouracil—skin cancer	5.68e-05	0.00142	CcSEcCtD
Vemurafenib—Constipation—Temozolomide—skin cancer	5.64e-05	0.00141	CcSEcCtD
Vemurafenib—Asthenia—Bleomycin—skin cancer	5.61e-05	0.00141	CcSEcCtD
Vemurafenib—Angiopathy—Docetaxel—skin cancer	5.6e-05	0.0014	CcSEcCtD
Vemurafenib—Mediastinal disorder—Docetaxel—skin cancer	5.56e-05	0.0014	CcSEcCtD
Vemurafenib—Chills—Docetaxel—skin cancer	5.54e-05	0.00139	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Fluorouracil—skin cancer	5.53e-05	0.00139	CcSEcCtD
Vemurafenib—Pruritus—Bleomycin—skin cancer	5.53e-05	0.00139	CcSEcCtD
Vemurafenib—Alopecia—Docetaxel—skin cancer	5.45e-05	0.00137	CcSEcCtD
Vemurafenib—Malnutrition—Docetaxel—skin cancer	5.37e-05	0.00135	CcSEcCtD
Vemurafenib—Erythema—Docetaxel—skin cancer	5.37e-05	0.00135	CcSEcCtD
Vemurafenib—Hypersensitivity—Dactinomycin—skin cancer	5.37e-05	0.00135	CcSEcCtD
Vemurafenib—ORM1—lymph node—skin cancer	5.35e-05	0.0171	CbGeAlD
Vemurafenib—Decreased appetite—Fluorouracil—skin cancer	5.28e-05	0.00132	CcSEcCtD
Vemurafenib—Dysgeusia—Docetaxel—skin cancer	5.26e-05	0.00132	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Fluorouracil—skin cancer	5.24e-05	0.00132	CcSEcCtD
Vemurafenib—Asthenia—Dactinomycin—skin cancer	5.23e-05	0.00131	CcSEcCtD
Vemurafenib—Body temperature increased—Temozolomide—skin cancer	5.21e-05	0.00131	CcSEcCtD
Vemurafenib—Back pain—Docetaxel—skin cancer	5.2e-05	0.0013	CcSEcCtD
Vemurafenib—Diarrhoea—Dactinomycin—skin cancer	4.99e-05	0.00125	CcSEcCtD
Vemurafenib—Vomiting—Bleomycin—skin cancer	4.97e-05	0.00125	CcSEcCtD
Vemurafenib—Rash—Bleomycin—skin cancer	4.93e-05	0.00124	CcSEcCtD
Vemurafenib—Dermatitis—Bleomycin—skin cancer	4.92e-05	0.00124	CcSEcCtD
Vemurafenib—Hypersensitivity—Temozolomide—skin cancer	4.86e-05	0.00122	CcSEcCtD
Vemurafenib—Body temperature increased—Fluorouracil—skin cancer	4.8e-05	0.0012	CcSEcCtD
Vemurafenib—Asthenia—Temozolomide—skin cancer	4.73e-05	0.00119	CcSEcCtD
Vemurafenib—ALB—lymph node—skin cancer	4.7e-05	0.015	CbGeAlD
Vemurafenib—Cough—Docetaxel—skin cancer	4.69e-05	0.00118	CcSEcCtD
Vemurafenib—Pruritus—Temozolomide—skin cancer	4.66e-05	0.00117	CcSEcCtD
Vemurafenib—Nausea—Bleomycin—skin cancer	4.64e-05	0.00116	CcSEcCtD
Vemurafenib—Vomiting—Dactinomycin—skin cancer	4.63e-05	0.00116	CcSEcCtD
Vemurafenib—Rash—Dactinomycin—skin cancer	4.6e-05	0.00115	CcSEcCtD
Vemurafenib—Arthralgia—Docetaxel—skin cancer	4.57e-05	0.00115	CcSEcCtD
Vemurafenib—Myalgia—Docetaxel—skin cancer	4.57e-05	0.00115	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	4.54e-05	0.00114	CcSEcCtD
Vemurafenib—Diarrhoea—Temozolomide—skin cancer	4.51e-05	0.00113	CcSEcCtD
Vemurafenib—Hypersensitivity—Fluorouracil—skin cancer	4.47e-05	0.00112	CcSEcCtD
Vemurafenib—Anaphylactic shock—Docetaxel—skin cancer	4.38e-05	0.0011	CcSEcCtD
Vemurafenib—Dizziness—Temozolomide—skin cancer	4.36e-05	0.00109	CcSEcCtD
Vemurafenib—Infection—Docetaxel—skin cancer	4.35e-05	0.00109	CcSEcCtD
Vemurafenib—Nausea—Dactinomycin—skin cancer	4.33e-05	0.00109	CcSEcCtD
Vemurafenib—Nervous system disorder—Docetaxel—skin cancer	4.3e-05	0.00108	CcSEcCtD
Vemurafenib—Pruritus—Fluorouracil—skin cancer	4.3e-05	0.00108	CcSEcCtD
Vemurafenib—Skin disorder—Docetaxel—skin cancer	4.26e-05	0.00107	CcSEcCtD
Vemurafenib—Vomiting—Temozolomide—skin cancer	4.19e-05	0.00105	CcSEcCtD
Vemurafenib—Rash—Temozolomide—skin cancer	4.16e-05	0.00104	CcSEcCtD
Vemurafenib—Diarrhoea—Fluorouracil—skin cancer	4.16e-05	0.00104	CcSEcCtD
Vemurafenib—Dermatitis—Temozolomide—skin cancer	4.15e-05	0.00104	CcSEcCtD
Vemurafenib—Headache—Temozolomide—skin cancer	4.13e-05	0.00104	CcSEcCtD
Vemurafenib—Hypotension—Docetaxel—skin cancer	4.1e-05	0.00103	CcSEcCtD
Vemurafenib—Dizziness—Fluorouracil—skin cancer	4.02e-05	0.00101	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Docetaxel—skin cancer	3.99e-05	0.001	CcSEcCtD
Vemurafenib—Nausea—Temozolomide—skin cancer	3.92e-05	0.000983	CcSEcCtD
Vemurafenib—ABCC1—lymph node—skin cancer	3.88e-05	0.0124	CbGeAlD
Vemurafenib—Vomiting—Fluorouracil—skin cancer	3.86e-05	0.000969	CcSEcCtD
Vemurafenib—Rash—Fluorouracil—skin cancer	3.83e-05	0.000961	CcSEcCtD
Vemurafenib—Dermatitis—Fluorouracil—skin cancer	3.83e-05	0.00096	CcSEcCtD
Vemurafenib—CYP3A4—female reproductive system—skin cancer	3.82e-05	0.0122	CbGeAlD
Vemurafenib—Decreased appetite—Docetaxel—skin cancer	3.81e-05	0.000956	CcSEcCtD
Vemurafenib—Headache—Fluorouracil—skin cancer	3.8e-05	0.000955	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Docetaxel—skin cancer	3.78e-05	0.00095	CcSEcCtD
Vemurafenib—Fatigue—Docetaxel—skin cancer	3.78e-05	0.000948	CcSEcCtD
Vemurafenib—CYP2D6—female reproductive system—skin cancer	3.76e-05	0.012	CbGeAlD
Vemurafenib—Constipation—Docetaxel—skin cancer	3.75e-05	0.000941	CcSEcCtD
Vemurafenib—Nausea—Fluorouracil—skin cancer	3.61e-05	0.000905	CcSEcCtD
Vemurafenib—Body temperature increased—Docetaxel—skin cancer	3.47e-05	0.00087	CcSEcCtD
Vemurafenib—Hypersensitivity—Docetaxel—skin cancer	3.23e-05	0.00081	CcSEcCtD
Vemurafenib—ABCG2—lymph node—skin cancer	3.21e-05	0.0103	CbGeAlD
Vemurafenib—Asthenia—Docetaxel—skin cancer	3.15e-05	0.000789	CcSEcCtD
Vemurafenib—CYP2D6—head—skin cancer	3.14e-05	0.01	CbGeAlD
Vemurafenib—Pruritus—Docetaxel—skin cancer	3.1e-05	0.000778	CcSEcCtD
Vemurafenib—Diarrhoea—Docetaxel—skin cancer	3e-05	0.000753	CcSEcCtD
Vemurafenib—Dizziness—Docetaxel—skin cancer	2.9e-05	0.000727	CcSEcCtD
Vemurafenib—Vomiting—Docetaxel—skin cancer	2.79e-05	0.000699	CcSEcCtD
Vemurafenib—Rash—Docetaxel—skin cancer	2.76e-05	0.000694	CcSEcCtD
Vemurafenib—Dermatitis—Docetaxel—skin cancer	2.76e-05	0.000693	CcSEcCtD
Vemurafenib—Headache—Docetaxel—skin cancer	2.75e-05	0.000689	CcSEcCtD
Vemurafenib—Nausea—Docetaxel—skin cancer	2.6e-05	0.000653	CcSEcCtD
Vemurafenib—RAF1—Adaptive Immune System—FOXO4—skin cancer	1.59e-05	0.000647	CbGpPWpGaD
Vemurafenib—BRAF—Disease—ENO2—skin cancer	1.57e-05	0.000642	CbGpPWpGaD
Vemurafenib—BRAF—Disease—SHH—skin cancer	1.57e-05	0.000642	CbGpPWpGaD
Vemurafenib—RAF1—ErbB1 downstream signaling—HRAS—skin cancer	1.57e-05	0.00064	CbGpPWpGaD
Vemurafenib—RAF1—Senescence and Autophagy in Cancer—HRAS—skin cancer	1.57e-05	0.00064	CbGpPWpGaD
Vemurafenib—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—skin cancer	1.56e-05	0.000638	CbGpPWpGaD
Vemurafenib—RAF1—Neuronal System—BRAF—skin cancer	1.56e-05	0.000637	CbGpPWpGaD
Vemurafenib—BRAF—NGF signalling via TRKA from the plasma membrane—KRAS—skin cancer	1.56e-05	0.000635	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—MC1R—skin cancer	1.55e-05	0.000631	CbGpPWpGaD
Vemurafenib—RAF1—VEGFA-VEGFR2 Pathway—HRAS—skin cancer	1.55e-05	0.000631	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by FGFR—IL6—skin cancer	1.54e-05	0.000626	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by Interleukins—HRAS—skin cancer	1.53e-05	0.000626	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—BRAF—skin cancer	1.53e-05	0.000625	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—GLI1—skin cancer	1.53e-05	0.000622	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signal transduction—NRAS—skin cancer	1.52e-05	0.000622	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR—NRAS—skin cancer	1.52e-05	0.000619	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by ERBB2—NRAS—skin cancer	1.51e-05	0.000616	CbGpPWpGaD
Vemurafenib—RAF1—Senescence and Autophagy in Cancer—IL6—skin cancer	1.5e-05	0.000613	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 signaling—NRAS—skin cancer	1.5e-05	0.000613	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by FGFR in disease—HRAS—skin cancer	1.49e-05	0.000609	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PTCH2—skin cancer	1.48e-05	0.000604	CbGpPWpGaD
Vemurafenib—RAF1—VEGFA-VEGFR2 Pathway—IL6—skin cancer	1.48e-05	0.000604	CbGpPWpGaD
Vemurafenib—RAF1—MAPK Signaling Pathway—NRAS—skin cancer	1.47e-05	0.000601	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by Interleukins—IL6—skin cancer	1.47e-05	0.000599	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by VEGF—HRAS—skin cancer	1.46e-05	0.000595	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by SCF-KIT—KRAS—skin cancer	1.46e-05	0.000595	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PLIN2—skin cancer	1.45e-05	0.000592	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by Insulin receptor—HRAS—skin cancer	1.45e-05	0.000591	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—SUFU—skin cancer	1.45e-05	0.00059	CbGpPWpGaD
Vemurafenib—ALB—Vitamin B12 Metabolism—IL6—skin cancer	1.44e-05	0.000588	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by FGFR in disease—IL6—skin cancer	1.43e-05	0.000583	CbGpPWpGaD
Vemurafenib—RAF1—Fc epsilon receptor (FCERI) signaling—NRAS—skin cancer	1.41e-05	0.000576	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 interactions—NRAS—skin cancer	1.41e-05	0.000576	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR in disease—NRAS—skin cancer	1.41e-05	0.000576	CbGpPWpGaD
Vemurafenib—BRAF—Focal Adhesion—HRAS—skin cancer	1.41e-05	0.000576	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	1.41e-05	0.000574	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR—NRAS—skin cancer	1.4e-05	0.000571	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by VEGF—IL6—skin cancer	1.4e-05	0.00057	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signaling of activated FGFR—KRAS—skin cancer	1.4e-05	0.000569	CbGpPWpGaD
Vemurafenib—RAF1—Regulation of Actin Cytoskeleton—KRAS—skin cancer	1.4e-05	0.000569	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by NGF—NRAS—skin cancer	1.39e-05	0.000568	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR in Cancer—NRAS—skin cancer	1.39e-05	0.000566	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by Insulin receptor—IL6—skin cancer	1.39e-05	0.000566	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by PDGF—NRAS—skin cancer	1.38e-05	0.000564	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by ERBB4—KRAS—skin cancer	1.37e-05	0.00056	CbGpPWpGaD
Vemurafenib—RAF1—TGF-beta Signaling Pathway—TP53—skin cancer	1.37e-05	0.000558	CbGpPWpGaD
Vemurafenib—RAF1—PDGFR-beta signaling pathway—HRAS—skin cancer	1.37e-05	0.000557	CbGpPWpGaD
Vemurafenib—BRAF—Transmission across Chemical Synapses—HRAS—skin cancer	1.36e-05	0.000553	CbGpPWpGaD
Vemurafenib—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—skin cancer	1.35e-05	0.000549	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—CSPG4—skin cancer	1.33e-05	0.000543	CbGpPWpGaD
Vemurafenib—BRAF—NGF signalling via TRKA from the plasma membrane—HRAS—skin cancer	1.32e-05	0.00054	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signal transduction—KRAS—skin cancer	1.31e-05	0.000535	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR—KRAS—skin cancer	1.31e-05	0.000532	CbGpPWpGaD
Vemurafenib—RAF1—EGF/EGFR Signaling Pathway—KRAS—skin cancer	1.31e-05	0.000532	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by ERBB2—KRAS—skin cancer	1.3e-05	0.00053	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 signaling—KRAS—skin cancer	1.29e-05	0.000527	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—SHH—skin cancer	1.29e-05	0.000527	CbGpPWpGaD
Vemurafenib—BRAF—Disease—FOXO4—skin cancer	1.28e-05	0.000524	CbGpPWpGaD
Vemurafenib—ALB—Folate Metabolism—TP53—skin cancer	1.28e-05	0.000522	CbGpPWpGaD
Vemurafenib—RAF1—MAPK Signaling Pathway—KRAS—skin cancer	1.27e-05	0.000517	CbGpPWpGaD
Vemurafenib—BRAF—NGF signalling via TRKA from the plasma membrane—IL6—skin cancer	1.27e-05	0.000517	CbGpPWpGaD
Vemurafenib—RAF1—NGF signalling via TRKA from the plasma membrane—NRAS—skin cancer	1.25e-05	0.00051	CbGpPWpGaD
Vemurafenib—RAF1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—skin cancer	1.25e-05	0.000509	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by SCF-KIT—HRAS—skin cancer	1.24e-05	0.000506	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—SMO—skin cancer	1.22e-05	0.000499	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—PTCH1—skin cancer	1.22e-05	0.000499	CbGpPWpGaD
Vemurafenib—RAF1—BDNF signaling pathway—HRAS—skin cancer	1.22e-05	0.000497	CbGpPWpGaD
Vemurafenib—RAF1—Fc epsilon receptor (FCERI) signaling—KRAS—skin cancer	1.22e-05	0.000496	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 interactions—KRAS—skin cancer	1.22e-05	0.000496	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR in disease—KRAS—skin cancer	1.22e-05	0.000496	CbGpPWpGaD
Vemurafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	1.21e-05	0.000493	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR—KRAS—skin cancer	1.21e-05	0.000492	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by NGF—KRAS—skin cancer	1.2e-05	0.000488	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR in Cancer—KRAS—skin cancer	1.19e-05	0.000487	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—PTGER4—skin cancer	1.19e-05	0.000486	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by PDGF—KRAS—skin cancer	1.19e-05	0.000485	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by SCF-KIT—IL6—skin cancer	1.19e-05	0.000484	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signaling of activated FGFR—HRAS—skin cancer	1.19e-05	0.000484	CbGpPWpGaD
Vemurafenib—ALB—Folate Metabolism—IL6—skin cancer	1.17e-05	0.000478	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—CSPG4—skin cancer	1.17e-05	0.000478	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by ERBB4—HRAS—skin cancer	1.17e-05	0.000476	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	1.14e-05	0.000467	CbGpPWpGaD
Vemurafenib—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—skin cancer	1.14e-05	0.000467	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signaling of activated FGFR—IL6—skin cancer	1.14e-05	0.000463	CbGpPWpGaD
Vemurafenib—RAF1—MAPK Signaling Pathway—TP53—skin cancer	1.13e-05	0.00046	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—GLI2—skin cancer	1.12e-05	0.000458	CbGpPWpGaD
Vemurafenib—RAF1—Insulin Signaling—HRAS—skin cancer	1.12e-05	0.000457	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—CDK4—skin cancer	1.12e-05	0.000456	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by ERBB4—IL6—skin cancer	1.12e-05	0.000456	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signal transduction—HRAS—skin cancer	1.12e-05	0.000455	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR—HRAS—skin cancer	1.11e-05	0.000453	CbGpPWpGaD
Vemurafenib—RAF1—EGF/EGFR Signaling Pathway—HRAS—skin cancer	1.11e-05	0.000453	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by ERBB2—HRAS—skin cancer	1.1e-05	0.00045	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—SHH—skin cancer	1.1e-05	0.00045	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 signaling—HRAS—skin cancer	1.1e-05	0.000448	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—RASA1—skin cancer	1.1e-05	0.000447	CbGpPWpGaD
Vemurafenib—RAF1—Disease—SHH—skin cancer	1.09e-05	0.000444	CbGpPWpGaD
Vemurafenib—RAF1—Disease—ENO2—skin cancer	1.09e-05	0.000444	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—ENO2—skin cancer	1.08e-05	0.000441	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—SHH—skin cancer	1.08e-05	0.000441	CbGpPWpGaD
Vemurafenib—RAF1—NGF signalling via TRKA from the plasma membrane—KRAS—skin cancer	1.08e-05	0.000439	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MC1R—skin cancer	1.07e-05	0.000437	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signal transduction—IL6—skin cancer	1.07e-05	0.000435	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR—IL6—skin cancer	1.06e-05	0.000433	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by ERBB2—IL6—skin cancer	1.06e-05	0.000431	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—GLI1—skin cancer	1.06e-05	0.00043	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 signaling—IL6—skin cancer	1.05e-05	0.000429	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—PTCH1—skin cancer	1.05e-05	0.000426	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—SMO—skin cancer	1.05e-05	0.000426	CbGpPWpGaD
Vemurafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	1.04e-05	0.000425	CbGpPWpGaD
Vemurafenib—BRAF—Neuronal System—HRAS—skin cancer	1.04e-05	0.000423	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 interactions—HRAS—skin cancer	1.03e-05	0.000422	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR in disease—HRAS—skin cancer	1.03e-05	0.000422	CbGpPWpGaD
Vemurafenib—RAF1—Fc epsilon receptor (FCERI) signaling—HRAS—skin cancer	1.03e-05	0.000422	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR—HRAS—skin cancer	1.02e-05	0.000418	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by NGF—HRAS—skin cancer	1.02e-05	0.000415	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—PTGER4—skin cancer	1.02e-05	0.000415	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	1.02e-05	0.000415	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR in Cancer—HRAS—skin cancer	1.02e-05	0.000414	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by PDGF—HRAS—skin cancer	1.01e-05	0.000412	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—SUFU—skin cancer	1e-05	0.000408	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 interactions—IL6—skin cancer	9.9e-06	0.000404	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR in disease—IL6—skin cancer	9.9e-06	0.000404	CbGpPWpGaD
Vemurafenib—RAF1—Fc epsilon receptor (FCERI) signaling—IL6—skin cancer	9.9e-06	0.000404	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR—IL6—skin cancer	9.81e-06	0.0004	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—NRAS—skin cancer	9.79e-06	0.000399	CbGpPWpGaD
Vemurafenib—RAF1—Focal Adhesion—HRAS—skin cancer	9.77e-06	0.000398	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by NGF—IL6—skin cancer	9.74e-06	0.000397	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR in Cancer—IL6—skin cancer	9.72e-06	0.000396	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by PDGF—IL6—skin cancer	9.68e-06	0.000395	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—NRAS—skin cancer	9.63e-06	0.000393	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—FOXO4—skin cancer	9.62e-06	0.000392	CbGpPWpGaD
Vemurafenib—RAF1—Transmission across Chemical Synapses—HRAS—skin cancer	9.38e-06	0.000382	CbGpPWpGaD
Vemurafenib—ALB—Selenium Micronutrient Network—IL6—skin cancer	9.31e-06	0.00038	CbGpPWpGaD
Vemurafenib—RAF1—NGF signalling via TRKA from the plasma membrane—HRAS—skin cancer	9.16e-06	0.000373	CbGpPWpGaD
Vemurafenib—BRAF—Disease—ERCC2—skin cancer	9.15e-06	0.000373	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—ENO2—skin cancer	9.05e-06	0.000369	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—FOXO4—skin cancer	8.99e-06	0.000367	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PLIN2—skin cancer	8.96e-06	0.000366	CbGpPWpGaD
Vemurafenib—RAF1—Disease—FOXO4—skin cancer	8.88e-06	0.000362	CbGpPWpGaD
Vemurafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	8.85e-06	0.000361	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—FOXO4—skin cancer	8.8e-06	0.000359	CbGpPWpGaD
Vemurafenib—RAF1—NGF signalling via TRKA from the plasma membrane—IL6—skin cancer	8.76e-06	0.000357	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—NRAS—skin cancer	8.71e-06	0.000355	CbGpPWpGaD
Vemurafenib—BRAF—Disease—TERT—skin cancer	8.57e-06	0.00035	CbGpPWpGaD
Vemurafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	8.47e-06	0.000345	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—KRAS—skin cancer	8.43e-06	0.000344	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—KRAS—skin cancer	8.29e-06	0.000338	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—ENO2—skin cancer	7.96e-06	0.000325	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—SHH—skin cancer	7.63e-06	0.000311	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—RASA1—skin cancer	7.58e-06	0.000309	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—KRAS—skin cancer	7.5e-06	0.000306	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PLIN2—skin cancer	7.4e-06	0.000302	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—SMO—skin cancer	7.23e-06	0.000295	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PTCH1—skin cancer	7.23e-06	0.000295	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CSPG4—skin cancer	7.23e-06	0.000295	CbGpPWpGaD
Vemurafenib—RAF1—Neuronal System—HRAS—skin cancer	7.18e-06	0.000293	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—HRAS—skin cancer	7.16e-06	0.000292	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	7.07e-06	0.000289	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—HRAS—skin cancer	7.04e-06	0.000287	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PTGER4—skin cancer	7.04e-06	0.000287	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—IL6—skin cancer	6.86e-06	0.00028	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—IL6—skin cancer	6.74e-06	0.000275	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—HRAS—skin cancer	6.37e-06	0.00026	CbGpPWpGaD
Vemurafenib—RAF1—Disease—ERCC2—skin cancer	6.33e-06	0.000258	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—ERCC2—skin cancer	6.27e-06	0.000256	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PLIN2—skin cancer	6.27e-06	0.000256	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—FOXO4—skin cancer	6.22e-06	0.000254	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—NRAS—skin cancer	6.22e-06	0.000254	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—IL6—skin cancer	6.1e-06	0.000249	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—NRAS—skin cancer	6.1e-06	0.000249	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—TERT—skin cancer	6e-06	0.000245	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CSPG4—skin cancer	5.97e-06	0.000243	CbGpPWpGaD
Vemurafenib—RAF1—Disease—TERT—skin cancer	5.93e-06	0.000242	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—TERT—skin cancer	5.88e-06	0.00024	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—NRAS—skin cancer	5.49e-06	0.000224	CbGpPWpGaD
Vemurafenib—BRAF—Disease—PTGS2—skin cancer	5.49e-06	0.000224	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—KRAS—skin cancer	5.35e-06	0.000218	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—NRAS—skin cancer	5.27e-06	0.000215	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—ERCC2—skin cancer	5.25e-06	0.000214	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—KRAS—skin cancer	5.25e-06	0.000214	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CSPG4—skin cancer	5.05e-06	0.000206	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—ENO2—skin cancer	4.91e-06	0.0002	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PLIN2—skin cancer	4.84e-06	0.000197	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—KRAS—skin cancer	4.73e-06	0.000193	CbGpPWpGaD
Vemurafenib—RAF1—Disease—BRAF—skin cancer	4.7e-06	0.000192	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—TP53—skin cancer	4.67e-06	0.00019	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—BRAF—skin cancer	4.66e-06	0.00019	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—ERCC2—skin cancer	4.62e-06	0.000189	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—HRAS—skin cancer	4.55e-06	0.000186	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—KRAS—skin cancer	4.54e-06	0.000185	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—HRAS—skin cancer	4.46e-06	0.000182	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—IL6—skin cancer	4.35e-06	0.000178	CbGpPWpGaD
Vemurafenib—BRAF—Disease—NRAS—skin cancer	4.27e-06	0.000174	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TERT—skin cancer	4.15e-06	0.000169	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—ENO2—skin cancer	4.06e-06	0.000165	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—HRAS—skin cancer	4.02e-06	0.000164	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CSPG4—skin cancer	3.9e-06	0.000159	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—HRAS—skin cancer	3.86e-06	0.000157	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—IL6—skin cancer	3.84e-06	0.000157	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	3.84e-06	0.000157	CbGpPWpGaD
Vemurafenib—RAF1—Disease—PTGS2—skin cancer	3.79e-06	0.000155	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—PTGS2—skin cancer	3.76e-06	0.000153	CbGpPWpGaD
Vemurafenib—BRAF—Disease—KRAS—skin cancer	3.67e-06	0.00015	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—NRAS—skin cancer	3.5e-06	0.000143	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ENO2—skin cancer	3.44e-06	0.00014	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—BRAF—skin cancer	3.29e-06	0.000134	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—NRAS—skin cancer	3.28e-06	0.000134	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—NRAS—skin cancer	3.2e-06	0.00013	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PTGS2—skin cancer	3.15e-06	0.000128	CbGpPWpGaD
Vemurafenib—BRAF—Disease—HRAS—skin cancer	3.12e-06	0.000127	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—KRAS—skin cancer	3.01e-06	0.000123	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—NRAS—skin cancer	2.99e-06	0.000122	CbGpPWpGaD
Vemurafenib—BRAF—Disease—IL6—skin cancer	2.99e-06	0.000122	CbGpPWpGaD
Vemurafenib—RAF1—Disease—NRAS—skin cancer	2.95e-06	0.00012	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—NRAS—skin cancer	2.93e-06	0.000119	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—ERCC2—skin cancer	2.85e-06	0.000116	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—KRAS—skin cancer	2.83e-06	0.000115	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PTGS2—skin cancer	2.77e-06	0.000113	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—KRAS—skin cancer	2.75e-06	0.000112	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	2.69e-06	0.00011	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ENO2—skin cancer	2.65e-06	0.000108	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—KRAS—skin cancer	2.57e-06	0.000105	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—HRAS—skin cancer	2.56e-06	0.000104	CbGpPWpGaD
Vemurafenib—RAF1—Disease—KRAS—skin cancer	2.54e-06	0.000104	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—KRAS—skin cancer	2.52e-06	0.000103	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—TP53—skin cancer	2.51e-06	0.000102	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—IL6—skin cancer	2.45e-06	0.0001	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—HRAS—skin cancer	2.4e-06	9.79e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—ERCC2—skin cancer	2.36e-06	9.61e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—HRAS—skin cancer	2.34e-06	9.54e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—TP53—skin cancer	2.29e-06	9.32e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IL6—skin cancer	2.24e-06	9.13e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—HRAS—skin cancer	2.19e-06	8.92e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—HRAS—skin cancer	2.16e-06	8.81e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—HRAS—skin cancer	2.14e-06	8.73e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—IL6—skin cancer	2.09e-06	8.53e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—NRAS—skin cancer	2.07e-06	8.43e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—IL6—skin cancer	2.07e-06	8.43e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—IL6—skin cancer	2.05e-06	8.36e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ERCC2—skin cancer	2e-06	8.14e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—KRAS—skin cancer	1.78e-06	7.26e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PTGS2—skin cancer	1.71e-06	6.98e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TP53—skin cancer	1.58e-06	6.45e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ERCC2—skin cancer	1.54e-06	6.28e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—HRAS—skin cancer	1.51e-06	6.17e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IL6—skin cancer	1.45e-06	5.9e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PTGS2—skin cancer	1.41e-06	5.76e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PTGS2—skin cancer	1.2e-06	4.88e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PTGS2—skin cancer	9.23e-07	3.77e-05	CbGpPWpGaD
